Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome following allogeneic hematopoietic stem cell transplant – a systematic review and meta-analysis

Allogeneic hematopoietic cell transplant (allo-HCT) has been shown to provide a significant overall survival (OS) benefit in patients with acute myeloid leukemia (AML) and intermediate or poor risk cytogenetics compared to patients that did not undergo allo-HCT in multiple studies.1-4 Similar OS benefits with allo-HCT have been documented in patients with higher-risk myelodysplastic syndromes (MDS).5, 6 The advent of reduced intensity conditioning (RIC) allo-HCT has expanded transplant eligibility for older patients and those with significant comorbidities with favorable outcomes compared to non-transplant strategies.

Source: Biology of Blood and Marrow Transplantation - September 19, 2021 Category: Hematology Authors: Jan Philipp Bewersdorf, Cecily Allen, Abu-Sayeef Mirza, Alyssa A. Grimshaw, Smith Giri, Nikolai A. Podoltsev, Lohith Gowda, Christina Cho, Martin S. Tallman, Amer M. Zeidan, Maximilian Stahl Source Type: research